Enveric Biosciences Inc. (ENVB)
| Bid | 1.41 |
| Market Cap | 2.79M |
| Revenue (ttm) | 142.9K |
| Net Income (ttm) | -2.18M |
| EPS (ttm) | -35.85 |
| PE Ratio (ttm) | -0.04 |
| Forward PE | -0.2 |
| Analyst | Buy |
| Ask | 1.6 |
| Volume | 130,534 |
| Avg. Volume (20D) | 2,860,105 |
| Open | 1.60 |
| Previous Close | 1.60 |
| Day's Range | 1.40 - 1.59 |
| 52-Week Range | 1.13 - 267.75 |
| Beta | 0.08 |
About ENVB
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosc...
Analyst Forecast
According to 1 analyst ratings, the average rating for ENVB stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 589.66% from the latest price.
Stock Forecasts
1 month ago · businesswire.com
Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. PatentCAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therap...
1 month ago · businesswire.com
Enveric Biosciences Announces Closing of $5 Million Public OfferingCAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule ...
1 month ago · businesswire.com
Enveric Biosciences Announces Pricing of $5 Million Public OfferingCAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule ...
